Later Line Therapeutic Decisions in Metastatic HCC: Case 2
Later Line Therapeutic Decisions in Metastatic HCC
January 2017
- A 74-year old female with a history of HCV-infection
- Prior treatment with interferon, achieving sustained virologic response
- Had recurrence of HCV
- CT scan showed a 6.5-cm single liver mass with arterial enhancement, venous phase washout, and main portal vein invasion
- ECOG=1
- Child-Pugh A
- Therapy was initiated with sorafenib at 400 BID
- Patient experienced grade 3 hand-foot skin reaction; dose reduction to 400 QD
- Patient experienced grade 3 diarrhea; dose reduction to 400 QOD
April 2017
- Follow-up scans show radiographic progression with lung metastases
Camrelizumab Plus Rivoceranib Maintains Survival Advantage in Untreated uHCC
June 2nd 2024With extended follow-up, the combination of investigational agents rivoceranib and camrelizumab demonstrated a significant survival benefit vs sorafenib in advanced, unresectable hepatocellular carcinoma.
Read More
Gholam Analyzes Treatment Outcomes for Advanced HCC in Child-Pugh B Population
April 28th 2024During a live Community Case Forum event in partnership with the Tennessee Oncology Practice Society, Pierre Gholam, MD, examined the current state of treatment for patients with hepatocellular carcinoma, looking in particular at what data is available for those with Child-Pugh B and C status who have poorer outcomes and have limited data from prospective clinical trials.
Read More
